Rigel Pharmaceuticals, Inc. ( RIGL ) announced that its ophthalmic JAK SYK inhibitor, R348, failed to meet the primary and …read more
Rigel’s R348 Fails in Phase II Study, Shares Down 13.6% – Analyst Blog
- by Bob Mitchell
Rigel Pharmaceuticals, Inc. ( RIGL ) announced that its ophthalmic JAK SYK inhibitor, R348, failed to meet the primary and …read more